This comment appeared on REGN about Optina and AMPE
Watch out Very closely for Optina
The new article, "Is This eye Drug Worth the Hype" mentions Optina as a contender to derail Eylea that of course would send REGN shares tumbling. The author states that some are doubtful of Optina but she doesn't back her comment up. The established scientific medical journal, Retina Today, featured a cover story on how exciting Optina is because it actually repairs the damaged blood vessels in the retina, because it works very fast and because it is a pill and not an injection.
REGN shareholders are advised to trade some of their shares into AMPE that just began trading on the NYSE today. Optina is positioning to make Eylea obsolete. Less
We would love to hear your scientific analysis ampioooooh since you appear to be satisfied with tjhe Retina Today article. But first, please share with us your credentials, scientific experience, PhD status so we can take you seriously. If not, then you don't count.